APC Inaugurates Osun Primary Election, Appeal Panels

National Chairman of the All Progressives Congress(APC), Prof. Nentawe Yilwatda, has inaugurated the Osun State governorship primary election and appeal committees.

The inauguration took place at the APC national secretariat in Abuja yesterday.

According to a post on the party’s X(Twitter), the primary election committee is chaired by Governor Monday Okpebholo of Edo State and the appeal panel has Governor Mai Mala Buni of Yobe State as chairman.

The primary election has Governors Lucky Aiyedatiwa(Ondo), Babajide Sanwo-Olu(Lagos), Sheriff Oborevwori(Delta), Abdullahi Sule(Nasarawa) and former governor Yahaya Bello(Kogi) as members while Hon. Solomon Maren is secretary.
Members of the appeal committee are deputy senate president Jibrin Barau, former deputy speaker of the House of Representatives, Hon. Idris Wase and deputy governor of Niger State, Comrade Mohammed Kesto with former FCT minister of state, Hon. Ramatu Tijjani Aliyu as secretary.
The primary election will be conducted through consensus.

APC had disqualified a former national secretary of the party, Senator Iyiola Omisore and six other aspirants from participating in its forthcoming governorship primary election in Osun State.

The others screened out were Babatunde Oralusi, Oyedotun Babayemi, Dr Akin Ogunbiyi, former Deputy Governor Benedict Alabi, Adegoke Rasheed Okiki and former senator Babajide Omoworare.
However, two aspirants; Mulikat Jimoh and Munirudeen Oyebamiji have been cleared to contest the primary election.

NAFDAC Mops Up Europharm Products Nationwide

The National Agency for Food and Drugs Administration and Control (NAFDAC) has alerted healthcare providers and the general public of the nationwide mop up of products by EUROPHARM Laboratories in Jos.

The agency on its X handle yesterday said it started the enforcement against Europharm Laboratories, Eurolink Nigeria Ltd. located at Plot Pl., 7354, Anglo Jos, New Ind. Area, following credible intelligence and regulatory surveillance.

It said investigations revealed that the company had been producing, selling and distributing multiple pharmaceutical and other regulated products without the necessary marketing authorisation.
According to NAFDAC, several products were discovered at the facility, many of which were being produced or distributed in violation of NAFDAC regulations during the investigation.

It noted that laboratory analysis was conducted on some of the products which further confirmed significant quality failures, raising serious public health concerns.

It revealed that results of analysis showed low Active Pharmaceutical Ingredients (API) content for Linmoxyn (Amoxicillin) suspension and Linmoxyn (Amoxicillin 500mg capsules) with the following outcome:

It said Linmoxyn (Amoxicillin suspension) failed analysis with API content of 13.9% and 18.4% which is far below acceptable limits, while Linmoxyn (Amoxicillin 500mg capsules) also failed, with API content of only 48.3 per cent, confirming it to be grossly substandard.

It said other products bearing various NAFDAC Registration Numbers (NRNs), were found at the Europharm Laboratories site during investigation:

NAFDAC explained that the risk of low API in medicines included treatment failure, antimicrobial resistance, and potential safety concerns to consumers.

It said the products included Linocloxin (Ampicillin 125mg & Cloxacillin 125mg) powder for oral suspension 100ml, Linromycine (Erythromycin) powder for suspension 100ml, Linocillin (Ampicillin) powder for oral suspension 50ml and Linmoxyn (Amoxicillin 125mg) suspension 60ml.

The others are Eurogyl (Metronidazole suspension) 50ml, Naflin (Cough Expectorant) 100ml Natacid (Magnesium Trisilicate suspension) 100ml, Navit-B Syrup (Vitamin B Complex) 100ml, Fountain B-12 (Blood Tonic) 100ml and 200ml.

It also included Vitamin-C Syrup 100ml, Eurogyl (Metronidazole) Tablet blister 10×10 tabs, Eurogyl (Metronidazole) x1000 tablets, Euramol (Paracetamol) x1000 tablets, Euramox (Mebendazole 100mg) tablets, Linotrim (Cotrimoxazole suspension) 50ml and Linoquine (Chloroquine Phosphate syrup 80mg/5ml) 60ml.

NAFDAC said all zonal directors and state coordinators had been directed to carry out surveillance and mop up the substandard products within the zones and states.

It urged all distributors, retailers, healthcare professionals and caregivers to exercise caution and vigilance within the supply chain to avoid the distribution, sale and use of the substandard products.

It also advised healthcare professionals and consumers to report any suspicion of sale of substandard and falsified medicines or medical devices to the nearest NAFDAC office. (NAN)